این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Journal of Pharmaceutical Care، جلد ۱۰، شماره ۳، صفحات ۱۶۷-۱۷۴
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Baricitinib: First Systemic Oral Drug for Alopecia Therapy
چکیده انگلیسی مقاله Baricitinib, a Janus kinase inhibitor, was originally approved as anti-rheumatic drug in 2017. In 2020, it was approved for the treatment of COVID-19 in selected hospitalized adults. Baricitinib received priority review designation for treatment of adult patients with severe alopecia areata and got USFDA approval on June 23, 2022 based on the results of 02 phase III trial: BRAVE-AA1 and BRAVE-AA2. In this review, we aim to summarize the different pharmacokinetic and pharmacodynamics aspects including drug interactions, adverse effects/black box warnings and their clinical relevance. We reiterate that oral JAK inhibitors are expensive, may carry significant risks, and are not yet recommended for routine treatment of alopecia areata. There is ongoing research on other topical and oral JAK inhibitors (tofacitinib and ruxolitinib), giving hope that better treatments for alopecia areata will become available in future.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Prashant Mishra
Deptartment of Pharmacology, Armed Forces Medical College, Pune-40, India.


| Sharmila Sinha
Deptartment of Pharmacology, Armed Forces Medical College, Pune-40, India.


| Sandeep Vihan
Deptartment of Pharmacology, Armed Forces Medical College, Pune-40, India.


| Navdeep Dahiya
Deptartment of Pharmacology, Armed Forces Medical College, Pune-40, India.


| Biju Vasudevan
Department of Dermatology, Armed Forces Medical College, Pune-40, India.
نشانی اینترنتی https://jpc.tums.ac.ir/index.php/jpc/article/view/510
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات